Skip to main
RZLT
RZLT logo

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc. demonstrates a promising outlook due to the substantial improvement in hypoglycemia observed with its drug candidate, ersodetug, which has proven well tolerated among participants. Additionally, insights from key opinion leader discussions indicate that up to 70% of congenital hyperinsulinism patients do not respond to standard of care treatments, highlighting a significant market opportunity for an efficacious therapy with a superior safety profile. The company's focus on addressing unmet medical needs through innovative therapies positions it favorably for revenue growth and value creation contingent upon successful product development and regulatory approvals.

Bears say

Rezolute Inc reported a net loss of $24.4 million for 4Q25, which is slightly below the consensus estimate of $25.9 million, indicating continued financial struggles. For FY25, the company is anticipated to incur a net loss of $74.4 million, which, while better than the consensus estimate of $95 million, still reflects significant ongoing financial burden. Furthermore, potential delays in regulatory approvals, exacerbated by pressures on the FDA's workforce, may hinder the company's ability to successfully bring its therapies to market, further impacting its financial outlook.

Rezolute (RZLT) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.